دورية أكاديمية

Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study

التفاصيل البيبلوغرافية
العنوان: Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study
المؤلفون: Ye, Hua, Liu, Shengyun, Xu, Jian, Chai, Kexia, He, Dongyi, Fang, Yongfei, Xie, Qibing, Liu, Huaxiang, Liu, Ying, Hua, Bingzhu, Hu, Jiankang, Zhang, Zhiyi, Zhou, Mingxuan, Zhao, Dongbao, Li, Yan, Jiang, Zhenyu, Wang, Meimei, Li, Jingyang, Zhang, Zhuoli, Li, Xiaomei, Li, Yang, Sun, Erwei, Bi, Liqi, Wei, Wei, Tie, Ning, He, Lan, Huang, Xiangyang, Zhang, Yan, Huang, Qingchun, Wang, Xiaofei, Liu, Xiangyuan, Li, Jing, Su, Yin
المساهمون: Chinese National Key Technology R&D Program
المصدر: Rheumatology and Therapy ; volume 10, issue 3, page 757-773 ; ISSN 2198-6576 2198-6584
بيانات النشر: Springer Science and Business Media LLC
سنة النشر: 2023
مصطلحات موضوعية: Immunology and Allergy, Rheumatology
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1007/s40744-023-00544-2
DOI: 10.1007/s40744-023-00544-2.pdf
DOI: 10.1007/s40744-023-00544-2/fulltext.html
الإتاحة: https://doi.org/10.1007/s40744-023-00544-2Test
حقوق: https://creativecommons.org/licenses/by-nc/4.0Test ; https://creativecommons.org/licenses/by-nc/4.0Test
رقم الانضمام: edsbas.C439124F
قاعدة البيانات: BASE